Liraglutide (Victoza, Saxenda)
Liraglutide (recombinant DNA origin)
Approved status applies to specific products, routes, and indications, not every use context discussed online.
An FDA-approved once-daily injection that mimics a natural gut hormone to control blood sugar in type 2 diabetes (Victoza) and promote significant weight loss in obesity (Saxenda). A major heart health trial showed it also reduces the risk of heart attack and cardiovascular death.
Safety Summary
GI adverse effects (nausea, vomiting, diarrhea) are dose-related, most common during initiation and dose escalation, and typically transient with continued use. Slow titration reduces GI intolerance. GI events are the most frequent cause of treatment discontinuation. A boxed warning exists for thyroid C-cell tumors observed in rodent studies (rats and mice) in a dose- and duration-dependent manner; human relevance is unknown. MTC remains a contraindication in at-risk patients. Long-term data (LEADER, real-world registries) do not show consistent increase in thyroid or pancreatic cancer in humans after adjustment for confounding and surveillance bias (LEADER neoplasm report, Diabetes Care 41(8):1663; US cohort analysis PMC8203194; Korean nationwide cohort). Weight regain is typical after discontinuation (-4.3-7.3 kg within 6-18 months) with HbA1c deterioration toward baseline. Psychiatric signals (suicidal ideation/behavior) were identified in FAERS but FDA requested removal of this warning for the GLP-1 class in January 2026.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-11]